ChemedFRA:CXM +1.03%75 Pretax Margin % is 13.51% as of Mar. 2026, which is 8% below its 10-year median of 14.75. GuruFocus rates FRA:CXM with a GF Score™ of 75/100 and a GF Value™ of €562.39 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Chemed ranks better than 79.34% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Chemed's Pre-Tax Income for the
three
months ended in Mar. 2026 was €77 Mil. Chemed's Revenue for the
three
months ended in Mar. 2026 was €569 Mil. Therefore, Chemed's pretax margin for the quarter that ended in Mar. 2026 was 13.51%.
The historical rank and industry rank for Chemed's Pretax Margin % or its related term are showing as below:
FRA:CXM'
s Pretax Margin % Range Over the Past 10 Years
Min: 7.01 Med: 14.75 Max: 19.04
Current: 13.74
FRA:CXM's Pretax Margin % is ranked better than 79.34% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 3.97
vs FRA:CXM: 13.74
Chemed (FRA:CXM) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Chemed Pretax Margin % Related Terms
Chemed Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Chemed's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CXM vs PACS, OPCH, CON: Pretax Margin % Comparison
For the Medical Care Facilities subindustry, Chemed's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemed Pretax Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Chemed's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Chemed's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemed (FRA:CXM) has a Pretax Margin % of 13.51% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Chemed and its competitors. This is near median its historical median of 14.75. Over the past decade, Chemed's Pretax Margin % has ranged from 7.01 to 19.04. According to the industry distribution chart, Chemed ranks #138 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 20.7%.
Is Chemed's Pretax Margin % too high?
Chemed's current Pretax Margin % of 13.51% is near median its 10-year median of 14.75. Over the past 10 years, this metric has ranged from a low of 7.01 to a high of 19.04. The Healthcare Providers & Services industry median Pretax Margin % is 3.97. Chemed's value of 13.51% is 240.3% above this industry median. Based on the distribution chart, Chemed ranks #138 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Chemed has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's Pretax Margin % compare to PACS and OPCH?
According to the Healthcare Providers & Services industry distribution chart, Chemed ranks #138 out of 668 companies for Pretax Margin %. This places Chemed in the top 21% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 3.97. Chemed's value of 13.51% is 240.3% above this benchmark. Historically, Chemed's own Pretax Margin % has ranged from 7.01 to 19.04 over the past decade. While the company's 10-year median is 14.75 vs. the industry median of 3.97, Chemed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Healthcare Providers & Services company?
The median Pretax Margin % among Healthcare Providers & Services companies is 3.97, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemed's current Pretax Margin % of 13.51% is 240.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Chemed and its competitors. For the Healthcare Providers & Services industry, the median Pretax Margin % is 3.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemed's current Pretax Margin % is 13.51%, which is near median its own 10-year median of 14.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Significantly Undervalued. The stock's GF Value™ is €562.39, compared to a current price of €394.00 — trading 29.9% below its estimated fair value. The current Pretax Margin % is 13.51%, which is near median its 10-year median of 14.75 and 240.3% above the Healthcare Providers & Services industry median of 3.97. Chemed's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Chemed (FRA:CXM), the current Pretax Margin % is 13.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemed (FRA:CXM) Overvalued in 2026?
Based on GuruFocus' analysis, Chemed stock appears to be undervalued.
The current stock price of €394.00 is trading 29.9% below its estimated GF Value™ of €562.39.
GuruFocus considers Chemed to be Significantly Undervalued.
Key valuation signals for FRA:CXM:
Pretax Margin %: 13.51% (near median its 10-year median of 14.75)
GF Value™: €562.39 vs. price of €394.00 (29.9% below fair value)
Industry Position: 240.3% above the Healthcare Providers & Services median (#138 of 668)
No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
75GF Score
Get the complete analysis for FRA:CXM
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CXM has been successfully added to your 
